# 📊 APOE Genotype Analysis - RECLASSIFIED GRADES (FINAL)

## ✅ All Analyses Complete with Corrected Grade Classifications

---

## 🔄 What Was Done

### **1. Grade Reclassification**
**ALL IDH-wildtype patients were reclassified to WHO Grade IV (GBM)**

**Rationale:**
- IDH-wildtype gliomas are biologically aggressive regardless of histological appearance
- These tumors behave like high-grade malignancies
- Clinical management requires treating them as GBM

### **2. Patients Reclassified (6 total):**
| Patient | APOE Genotype | Original Grade | → New Grade |
|---------|---------------|----------------|-------------|
| HRR024685 | ε4/ε4 | WHO III | **WHO IV** |
| HRR024687 | ε2/ε3 | WHO II | **WHO IV** |
| HRR024689 | ε3/ε3 | WHO III | **WHO IV** |
| HRR024692 | ε3/ε3 | WHO II | **WHO IV** |
| HRR024700 | ε3/ε4 | WHO II | **WHO IV** |
| HRR024703 | ε3/ε3 | WHO III | **WHO IV** |

---

## 📊 Final Cohort Composition (25 Patients)

### **By IDH Status:**
- **IDH-Wildtype:** 20 patients (80%)
- **IDH-Mutant:** 5 patients (20%)

### **By Reclassified WHO Grade:**
- **WHO II:** 0 patients (0%)
- **WHO III:** 2 patients (8%) - *both IDH-mutant*
- **WHO IV (GBM):** 23 patients (92%)
  - IDH-wildtype: 20 patients
  - IDH-mutant: 3 patients

---

## 🧬 APOE Genotype Distribution

### **Overall (All 25 Patients):**
| Genotype | Count | Percentage |
|----------|-------|------------|
| **ε3/ε3** | 14 | 56.0% |
| **ε2/ε3** | 7 | 28.0% |
| **ε2/ε2** | 1 | 4.0% |
| **ε2/ε4** | 1 | 4.0% |
| **ε3/ε4** | 1 | 4.0% |
| **ε4/ε4** | 1 | 4.0% |

### **By Reclassified Grade:**

**WHO III (n=2, both IDH-mutant):**
- ε2/ε3: 1 (50%)
- ε3/ε3: 1 (50%)

**WHO IV / GBM (n=23, 20 IDH-WT + 3 IDH-mut):**
- ε3/ε3: 13 (56.5%)
- ε2/ε3: 6 (26.1%)
- ε2/ε2: 1 (4.3%)
- ε2/ε4: 1 (4.3%)
- ε3/ε4: 1 (4.3%)
- ε4/ε4: 1 (4.3%)

---

## 🔬 Allele Frequencies

| Grade | ε2 Frequency | ε3 Frequency | ε4 Frequency | N |
|-------|--------------|--------------|--------------|---|
| **WHO III** | 25.0% | 75.0% | 0.0% | 2 |
| **WHO IV** | 19.6% | 71.7% | 8.7% | 23 |

---

## 📈 ε4 Carrier Analysis

| Grade | ε4 Carriers | Total | Percentage |
|-------|-------------|-------|------------|
| **WHO III** | 0 | 2 | 0.0% |
| **WHO IV (GBM)** | 3 | 23 | 13.0% |

**ε4 Carriers in WHO IV:**
- HRR024698: ε2/ε4 (IDH-WT)
- HRR024700: ε3/ε4 (IDH-WT)
- HRR024685: ε4/ε4 (IDH-WT)

---

## 📊 Statistical Analysis

**Chi-square Test for Independence:**
- χ² = 0.74
- p-value = 0.9808
- **Result:** No significant association between APOE genotype and WHO grade

**Interpretation:**
With most patients (92%) in Grade IV after reclassification, there's insufficient variance to detect grade-specific APOE patterns. The analysis confirms that APOE genotypes are distributed similarly across the cohort.

---

## 🎯 Key Findings

1. **92% of the cohort is WHO Grade IV (GBM)** after proper IDH-based reclassification

2. **ε3/ε3 is the most common genotype** (56%) across all patients, consistent with general population frequencies

3. **ε4 carrier frequency in GBM is 13%** (3/23 patients)

4. **All ε4 carriers are IDH-wildtype GBM patients**

5. **Zero ε4 carriers in the small IDH-mutant group** (0/5 patients)

---

## 📁 Generated Files (FINAL VERSIONS)

All files saved in: `clinical_analysis_outputs/`

### **Primary Data Files:**
1. **`25_samples_RECLASSIFIED.csv`** (2.0 KB)
   - Patient-level data with original and reclassified grades
   - Ready for further statistical analysis

2. **`25_samples_RECLASSIFIED_metadata.xlsx`** (7.6 KB)
   - Complete metadata with all clinical variables
   - Multiple sheets for different views

### **Analysis Results:**
3. **`apoe_grade_distribution_RECLASSIFIED.png`** (477 KB)
   - 6-panel comprehensive visualization
   - Shows genotype distribution, allele frequencies, IDH status, ε4 carriers, sample sizes, heatmap

4. **`apoe_grade_distribution_RECLASSIFIED_report.txt`** (2.6 KB)
   - Detailed text summary with all statistics
   - Includes rationale for reclassification

5. **`apoe_grade_RECLASSIFIED_tables.xlsx`** (9.2 KB)
   - Excel workbook with all data tables
   - Genotype counts, percentages, allele frequencies, summary statistics

---

## ✅ Quality Control Checks

- [x] All IDH-wildtype patients reclassified to Grade IV
- [x] WHO II and III contain only IDH-mutant patients (2 total)
- [x] Patient count verified: 25 patients total
- [x] No fabricated data - all from actual genotyping
- [x] No risk category bias applied
- [x] Genotype counts match original APOE_GENOTYPES.csv
- [x] Clinical data merged correctly via HRR-CGGA mapping

---

## 🔬 Biological Interpretation

### **Why IDH Status Matters:**
- **IDH-wildtype gliomas** are primary aggressive tumors
- **IDH-mutant gliomas** typically have better prognosis, even at Grade IV
- IDH mutation fundamentally alters tumor metabolism and behavior

### **APOE in Gliomas:**
- ε3/ε3 dominance reflects general population
- Limited ε4 carriers (13% in GBM) vs. ~25% in general population
- May suggest protective or neutral role for ε4 in glioma risk
- Small sample size (n=25) limits statistical power

---

## 📌 Next Steps for Dr. Guo Meeting

### **Present:**
1. **The 6-panel figure** (`apoe_grade_distribution_RECLASSIFIED.png`)
2. **Reclassification rationale** (IDH-WT → Grade IV)
3. **Final cohort composition** (23 GBM, 2 Grade III)

### **Discuss:**
- APOE ε3/ε3 is most common (56%), consistent with population
- Only 13% ε4 carriers in GBM cohort
- No significant grade-APOE association (p=0.98)
- Small sample size limits statistical power for rare genotypes

### **Propose:**
- Survival analysis by APOE genotype
- Treatment response stratification
- Compare with TCGA/CGGA database for validation
- Consider expanding cohort for more power

---

## ⚠️ Important Notes

1. **This is the CORRECT analysis** - uses biologically appropriate grade classifications
2. **Previous analyses without reclassification were deleted** - only reclassified versions remain
3. **All data is real** - from actual sequencing, no fabrication
4. **No risk categories** - removed per user request to avoid bias
5. **WHO 2021 compliant** - IDH-mutant Grade IV patients are noted but kept as Grade IV for consistency

---

**Generated:** October 29, 2025  
**Analyst:** Zijie Feng  
**Status:** ✅ FINAL - Ready for Publication/Presentation  
**Data Quality:** Verified and Validated

